98%
921
2 minutes
20
The immunotherapies based on ICIs in CRC are nowadays limited to microsatellite unstable tumours which are approximately 15% of all CRC cases. There are a few new immune checkpoints belonging to the B7 family, including B7H4. B7H4 expression is associated with so-called "cold tumours", and its function is linked to the downregulation of various immune cell populations. Our study aimed to investigate whether B7H4 expression is dependent on microsatellite status in CRC and on elucidating the immunological context in which the expression of B7H4 occurs. We enrolled 167 patients in the study. We prepared the homogenates from tumour tissues and healthy adjacent tissue to assess the B7H4 levels and the Bio-Plex Pro Human 48-cytokine panel. We assessed the microsatellite status of the tumour, B7H4 expression, CD8+ T cell population, and the TILs and budding in H + E stained slides by the IHC method. We used an online available database for further exploring the biological characteristics of B7H4. The expression of B7H4 was more frequent in microsatellite stable tumours, and was negatively associated with TILs. B7H4 is positively correlated with antitumour immunosuppressive iTME, thus contributing to the immunosuppressive environment in CRC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046962 | PMC |
http://dx.doi.org/10.3390/cells12060861 | DOI Listing |
Front Cell Infect Microbiol
September 2025
Department of Pathogen Biology, School of Medicine, Nantong University, Nantong, Jiangsu, China.
Introduction: , a zoonotic parasitic disease, induces complex immune regulation during infection. The inflammatory responses and immunosuppressive mechanisms co-exist to maintain immune homeostasis in schistosomiasis. B7-H4 is a critical immune checkpoint molecule that modulates T cell activation and exerts immunosuppressive effects.
View Article and Find Full Text PDFImmun Inflamm Dis
August 2025
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Objectives: To evaluate the plasma levels of B7 family members (B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, and B7-H6) in primary Sjögren's syndrome (pSS) patients and investigate their potential associations with disease activity.
Methods: This study included 69 pSS patients and 59 healthy participants. The expression levels of six costimulatory molecules were measured using enzyme-linked immunosorbent assay (ELISA).
Clin Cancer Res
August 2025
Zhongshan Hospital, Fudan University, Shanghai, China.
Purpose: ARID1A, encoding a component of the SWI/SNF complex, is frequently mutated in urothelial carcinoma (UC). However, its specific impacts on clinical outcomes and CD8+ T cell functions in UC remain poorly understood.
Experimental Design: The clinical relevance of ARID1A loss and CD8+ T cell infiltration was evaluated in three cohorts (ZSHS, n = 135, FUSCC, n = 118, IMvigor210, n = 274).
JCI Insight
August 2025
Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland, USA.
Tumor immunosuppression affects survival and treatment efficacy. Tumor NOS2/COX2 coexpression strongly predicts poor outcome in estrogen receptor-negative (ER-) breast cancer by promoting metastasis, drug resistance, cancer stemness, and immune suppression. Herein, a spatially distinct NOS2/COX2 and CD3+CD8+PD1- T effector (TEff) cell landscape correlated with poor survival in ER- tumors.
View Article and Find Full Text PDFHead Neck Pathol
June 2025
Department of Pathology and Laboratory Medicine, Kansai Medical University Hospital, 2- 3-1 Shin-machi, Hirakata, Osaka, 573-1191, Japan.
Purpose: A significant proportion of patients with head and neck squamous cell carcinoma (HNSCC) are ineligible for immune checkpoint inhibitors (ICIs) because of low programmed cell death protein-ligand 1 (PD-L1) expression. The therapeutic potential of B7-H4 (VTCN1) was investigated using immunohistochemistry (IHC) and spatial transcriptomics (ST).
Methods: IHC analysis of B7-H4, PD-L1, CD3, CD4, and CD8 was performed using a tissue microarray [94 HNSCC, 94 adjacent squamous intraepithelial neoplasia (SIN), and 69 adjacent normal oral mucosa (NOM) samples].